UNITED-FIRST-PARTNERS
9.5.2017 16:33:12 CEST | Business Wire | Press release
United First Partners ("UFP"), a leading Special Situations Investment & Advisory Group is pleased to announce it has entered into a strategic alliance with the Mariana Group (“Mariana”), a leading Derivatives and Structured Products brokerage group, which is fully FCA regulated and based in London. The combination of UFP and Mariana creates a mid-sized financial services group with a strong reputation in the Equities and Derivatives space. Consequently, Mariana’s regulated entity has been renamed Mariana UFP LLP (FRN 551170) and oversee in excess of 70 professionals in London covering a broad spectrum of value added financial products and services.
This strategic alliance will add to UFP’s current offering in Equities in Europe, as Mariana is a primarily Derivatives and Structured Products brokerage operation, with a strong reputation amongst its peers. UFP and Mariana anticipate significant synergies across business lines in relation to the regulatory challenges expected in the years to come.
UFP and Mariana have upgraded their facilities and entered into new clearing arrangements in order to give Mariana UFP the tools to compete at the highest level.
In the US, UFP LLC (SEC regulated and member of FINRA and SIPC) will continue to operate as a standalone entity, although UFP and Mariana have plans to significantly expand the existing scope of activities in the region, in particular in the Derivatives segment.
Michael Hadjedj, Co-founder of UFP commented: “We are very excited by the strategic alliance we have formed with Mariana. We believe that our industry needs consolidation and Mariana UFP wants to be at the heart of it. UFP’s strong niche research offering combined with Mariana’s cross-asset execution platform and large market share in the derivatives space is a powerful combination to seize opportunities in our industry.”
Daniel Hawkins, Co-founder and CEO of Mariana added, “We are very pleased to join forces with UFP, which brings to Mariana access to a strong research franchise to complement our existing Macro-Economic and Derivative Strategy offering. We are now working towards generating synergies across the group’s business lines, and leveraging on UFP’s presence in the US. We are also preparing actively for the transition to MIFID II in Europe and feel our enlarged group is well positioned.”
About United First Partners
United First Partners (“UFP”) is a global leading Special Situations Investment & Advisory Group, offering a wide range of merchant banking and investment advisory services to institutional and private clients. These services range from sale and purchase of strategic assets to corporate finance, debt and equity capital markets and wealth management.
Our strategy and core values allowed us to build an extensive customer base including leading hedge funds, private equity funds, long-only funds, corporates, sovereign wealth funds and family offices. Our achievements, independence, unique business model and strong reputation have enabled UFP to become an attractive and reliable partner for business associates and talented professionals.
Over the past 6 years, UFP has been recognised as the #1 independent Pan European Special Situations research by industry leading survey Extel.
For further details, please visit www.utdfirst.com
About Mariana Capital
Mariana Capital Markets is a diversified, independent financial services intermediary providing bespoke advisory and strategy services. The firm was founded in 2009 to create and distribute innovative, high performance investment solutions and provide the highest quality service to our clients.
From our headquarters in the City of London, we offer global financial solutions ranging from Market Strategy and Tax Advisory to Structured Products and Estate Planning Solutions.
These services complement our status as a market leading execution venue for Cash Equities, Equity Futures and Options, Commodities, and Fixed Income products.
For further details, please visit www.marianainvestments.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170509006106/en/
Contact:
Press Enquiries:
Sara Caniggia
+44 207 050 6803
media@utdfirst.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom